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Abstract
Background: In Mozambique cervical cancer is a public health threat, due to its high incidence and limited access
to early diagnosis of precancerous lesions. International organisations are supporting the introduction of human
papillomavirus (HPV) vaccines in low- and middle-income countries. Some of these countries recently conducted
demonstration programmes, which included evaluation of acceptability, coverage, and practicality of
implementation and of integration in existing programmes. Information on costs of delivering the vaccine is
needed to overcome the challenges of reaching vaccine potential recipients in rural and remote areas.
Methods: We estimated the financial and economic costs of delivering HPV vaccination to ten-year-old girls at
schools for the first vaccination cycle of the demonstration programme in the Manhiça district (southern
Mozambique), delivered throughout 2014. We also estimated costs of an alternative scenario with a reduced
number of doses and personnel, which was analogous to the second vaccination cycle delivered throughout 2015.
Cost estimates followed a micro-costing approach and included interviews with key informants at different
administrative levels through the administration of standard questionnaires developed by the World Health
Organisation.
Results: Considering only data from the first vaccination cycle (2014), which consisted in the administration of
three doses, the average economic cost was US$17.59 per dose and US$52.29 per fully-immunised girl (FIG).
Financial cost per dose (US$6.07) and per FIG (US$17.95) were substantially lower. The economic cost was
US$15.53 per dose and US$31.14 per FIG when estimating an alternative cost scenario with reduced number of
doses and personnel.
Conclusions: The average economic cost per dose was lower than the ones recently reported for low- and
middle-income countries. However, our estimation of the financial cost per FIG was higher than the ones
observed elsewhere (ranging from US$2.49 in India to US$20.36 in Vietnam) due to the high percentage of
out-of-school girls which, reduced vaccine coverage and, therefore, reduced the denominator. Due to budget
constraints, if Mozambique is to implement nation-wide HPV vaccination targeted to ten-year-old girls at
schools, a reduction in personnel costs should be operated either by restricting the outreach vaccinator team
or the number of supervision visits.
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Background
Cervical cancer affected 570,000 women worldwide in
2018 and 311,000 died of the disease [1]. Cervical cancer
is currently the most common type of cancer affecting
women in low- and middle-income countries (LMICs)
[2]. This is also the case in Mozambique, where 5,622
women were diagnosed with cervical cancer and 4,061
women died of the disease in 2017 [3]. Cervical cancer
has also been identified to be the most common type of
cancer between 1991 and 2008 in the country’s main
Central Hospital [4]. However, due to underdiagnoses,
any reported figure is very likely to be an underestima-
tion of the real disease burden.
Human papillomavirus (HPV) is a necessary cause
of cervical cancer [5]. Specifically, HPV 16 and 18
are the two genotypes responsible for about 70% of
cervical cancer cases [6]. The development of safe
and efficacious vaccines against the two high-risk
HPV genotypes raised hopes of reducing the global
incidence of cervical cancer. While most high-in-
come countries progressively adopted publicly
funded HPV vaccination programmes since 2006, few
LMICs could afford its implementation due to the
high vaccine price [7, 8]. To improve access in
LMICs, an agreement to reduce HPV vaccines’ price
to US$5 per dose took place in 2011 between manu-
facturers and the GAVI Vaccine Alliance, formerly
known as the Global Alliance for Vaccination and
Immunisation [9]. Only then, GAVI, national govern-
ments and other international organisations
supported HPV vaccination programmes in LMICs
with a yearly gross national income (GNI) per capita
not higher than US$1,580 [10, 11].
In sub-Saharan Africa, preliminary estimates suggest
that, under the assumption of high coverage and lifelong
protection, the introduction of the vaccine is expected to
result in high health gains in terms of both number of
cancer cases and disability-adjusted life years (DALYs)
averted [12]. However, even after high vaccine price re-
ductions, one of the key issues associated with HPV vac-
cination is its cost of delivery and administration,
particularly in rural and remote areas [13, 14]. Despite
the efforts made, the unsubsidised cost of HPV vaccin-
ation is still higher than the majority of vaccines. Its de-
livery is challenging as the target group for HPV
vaccination (girls between nine and 13 years of age) [6]
differs markedly from the routine expanded programme
on immunisation (EPI), which targets infants and young
children [15].
The challenge of reaching the HPV vaccination target
group is the absence of an entry point at health facility
level, calling for the need to reach the girls outside the
health system stricto sensu. Vaccination at schools has
been suggested as an effective strategy to maximise both
vaccine coverage [16] and the number of fully-immu-
nised girls (FIGs) [17]. However, in LMICs some girls
may be found absent from school on vaccination days,
implying the need for establishing additional community
strategies to maximise the reach [18]. These outreach
approaches require high level of resources to identify the
target population, engage them, train health profes-
sionals, teachers and other stakeholders, and finally de-
liver the vaccine [19–22].
In recognition of the high burden of cervical cancer in
Mozambique, new efforts have been in place to reduce
the disease burden in the country. Such efforts included
a cervical cancer screening programme launched in 2009
[23], the consolidation of a cancer registry based at the
Maputo Central Hospital [4], and the evaluation of
introducing HPV vaccination to pre-adolescent girls as
part of the national routine EPI by 2021. Under this
framework, a demonstration programme was carried out
in Mozambique consisting of vaccinating ten-year-old
girls at schools, health facilities and communities in
three districts: Manhiça, Manica and Mocímboa da
Praia; south, centre and north of the country, respect-
ively. The programme ran in two cycles, years 2014 and
2015, and was implemented as a three-dose schedule of
Bivalent Cervarix® during the first year and a two-dose
schedule during the second year; both providing a
complete immunisation [24]. The programme imple-
mentation in Manhiça district followed a school-based
approach and was funded and supported by GAVI as
part of the initiative to introduce HPV vaccination in
LMICs [25]. The Mozambican government funded the
delivery in the two other districts [24]. This study esti-
mated the costs associated with the demonstration
programme of HPV vaccination during the 2014 cycle in
the Manhiça district, and developed an alternative cost
scenario for future implementation.
Methods
Study setting
The study was carried out in Manhiça, a semi-rural dis-
trict 80 km north of Maputo city. With 229,539 inhabi-
tants in 2013 [26], the population is unevenly distributed
across the district with concentrations in the two main
towns, Manhiça and Xinavane. There are some commer-
cial activities on the main road crossing the district
South-North [26], but most of the population lives in
precarious dwellings and live of subsistence farming.
According to the National Institute of Statistics 92 pri-
mary schools and 2,974 girls ten years of age are present
in the district [24, 26]. Manhiça encompasses one dis-
trict and one rural hospital, 13 health facilities and one
health post, covering the six administrative posts [26].
EPI services are available in 12 of the health facilities.
Adjacent to the district hospital, the Manhiça Health
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Research Centre (in Portuguese Centro de Investigação
em Saúde de Manhiça, CISM) operates a health and
demographic surveillance system in the district, which
monitors the entire population’s vital events at commu-
nity level and records paediatric outpatients and hospital
admissions since 1996 [27].
Data collection approach
Primary data collection involved interviews with experts,
referred to as key informants in this study, at the national,
district (Manhiça) and sub-district levels (health facilities),
to gather information on the use of resources during the
first year demonstration programme [28]. Interviews with
informants at different administrative levels allowed a bet-
ter understanding of the overall vaccination process
already in place and the relationships between central, dis-
trict and local management of the vaccine procurement,
delivery and administration. While representatives at the
national level provided a wider view on both the current
EPI state in Mozambique and on the challenges and re-
sources needed for the potential inclusion of the new vac-
cine, local health professionals provided a day-to-day
perspective of the use of resources. Data were comple-
mented with specific information documented on the
demonstration programme [24, 29], such as the number
of schools and health facilities involved in the study, num-
ber of ten-year-old girls enrolled at school and registered
in the district or data on drop-out rates, coverage and vac-
cination rounds.
Interviews were carried out face-to-face, unless not
possible. If not possible, interviewees were contacted by
phone or e-mail. Key representatives from the Ministry
of Health (MoH) and Education (MoE) at central level
were interviewed, including the current EPI Chief, EPI
logistic head, EPI financial head, EPI data manager and
the responsible of the Special Programmes Directorate
in the MoE. At district level, the responsible of school
health promotion at the Manhiça District Directorate of
Education, a medical technician, a physician, the Chief
Medical Officer at the Manhiça District Hospital, as well
as representatives of CISM. Key implementation part-
ners involved in the programme were included in the in-
terviewees group; namely Village Reach, Fundação para
o Desenvolvimento da Comunidade (FDC) and the
United Nations International Children’s Emergency
Fund (UNICEF).
Standard structured questionnaires developed by the
World Health Organisation (WHO) were administered
to interviewees [20]. Questionnaires used for data collec-
tion can be found in Additional file 1: S1. Questions in-
quired about the resources needed for the introduction
and management of the new vaccine, including training
and mobilisation campaigns, additional resources for the
cold-chain and supervision, among others [30]. This
standardised procedure allowed comparisons with other
demonstration programmes held in other LMICs [21].
Data from questionnaires were incorporated in a spread-
sheet prepared by the WHO for analytical and graphical
data aggregation [30].
Costing approach
The costs were initially retrieved in Mozambican meti-
cais (MT) and later converted to US dollars (US$), using
the official exchange rate published by the World Bank
for the year 2014 (1US$ = 31.35MT) [31]. A linear de-
preciation approach was used to capture inflation and
the value loss of certain products subject to devaluation,
such as vehicles, using a standard discount rate of 3%
per year [32].
The cost estimates for delivering HPV vaccination in
Manhiça district through schools were based on a mi-
cro-costing approach in which all resources and costs
associated to the purchase, storage, distribution and de-
livery the vaccine were quantified, including all indirect
resources and costs related to those actions (such as,
training and social mobilisation activities). Following an
ingredient approach [32], every input was the result of
the quantity of resource used multiplied by its
correspondent unit cost [15].
Costs were differentiated between financial and eco-
nomic [20]. While financial costs referred only to the
use of resources paid by the MoH to execute the
programme, economic costs also included the use of
resources that did not necessarily imply a payment
from the MoH. Thus, economic costs consisted of fi-
nancial costs plus the use of resources already exist-
ing in the health system or donated by partners for
the programme. Economic costs included: (1) the vac-
cine price, as it was subsidised by GAVI [19, 21]; (2)
the use of cold-chain excess capacity; (3) the time of
volunteers or other workers whose salary was not
paid by the programme (considered as opportunity
cost of time) [19, 21], and (4) capital costs already
existing in the system and used during the
programme, such as means of transport used for
microplanning, training or service delivery. Moreover,
distinction was done between incremental or full
costs, when relevant [33]. While full cost analysis es-
timated the costs of all resources used for vaccine ad-
ministration, independently from using already
existing or not yet available resources, incremental
analysis estimated the costs of all the additional re-
sources not yet available to add a new vaccine, such
as storage, transport or salaries.
Cold-chain needs were estimated according to available
information on the current multi-tiered distribution sys-
tem and the cold-chain management and needs [34, 35].
In 2014 the cold-chain infrastructure benefitted from
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excess capacity and no extra-investment was required for
the sake of the demonstration project [35]. The use of
existing excess capacities was estimated as the number of
doses administered during the first vaccination cycle
multiplied by the vaccine supply chain cost per dose esti-
mated for a region in southern Mozambique [34]. The
value of existing capacities was considered economic cost.
Costs were additionally categorised into introduction,
recurrent, cold-chain supplement and other costs.
Introduction costs, which occur at programme incep-
tion, included the value of resources required to start
the implementation of the new vaccination. These costs
consisted of (1) microplanning and training, (2) social
mobilisation and information, education and communi-
cation (IEC) activities. Introduction costs were annual-
ised over five years using a discount rate of 3%, as they
were assumed to have a mid-term duration as part of
vaccine implementation but only the first year amount
was imputed to the programme costs of the 2014 cycle
[15, 22]. Recurrent costs referred to the regular costs
for vaccine delivery; such as (1) vaccine procurement,
(2) service delivery, (3) supervision and monitoring and
(4) other recurrent costs. The vaccine price, as part of
the vaccine procurement cost, was considered
economic and not financial cost [19], but custom clear-
ance, syringes and safety boxes were considered both fi-
nancial and economic costs.
Finally, estimated costs were expressed as average finan-
cial and economic cost per dose and per FIG. The average
cost per dose was the sum of total costs divided by the sum
of all doses delivered, which consisted of doses adminis-
tered and the vaccine wastage. The average cost per FIG
was computed as total introduction and cold-chain costs
divided by the total target population plus total recurrent
costs divided by the number of FIGs. The number of FIGs
was defined as the sum of girls being administered three
doses for the demonstration programme (2014 cycle) and
two doses for the alternative scenario. Analytical expres-
sions of the average cost per dose and FIG can be found in
the Additional file 1: S2.
Cost of alternative scenario
The programme was implemented over two vaccination
cycles: lessons learnt in the first cycle (2014) helped im-
prove the implementation of the second cycle (2015).
Data on resources used were not collected over the sec-
ond cycle. However, the second cycle inspired the esti-
mate of resources needed for a potentially more efficient
scenario, alternative to the first one, based on: (1) a re-
duction in the number of doses to fully-immunise a girl
(from three to two), following WHO recommendations
[36]; (2) a decrease in outreach and supervision teams to
one vaccinator, one teacher and one supervisor; and (3)
two community visits of outreach services for each
health facility catchment area to increase vaccination
coverage and reach girls absent from schools (by taking
into account 12 health facilities in the district, a total 24
visits were assumed and the associated costs were con-
sidered as economic).
Results
The Manhiça demonstration programme
In total 20 key participants were contacted, of which 13
were interviewed and provided the inputs needed to as-
sess the programme costs. The remaining seven were
unavailable for interview. A list of interviewees can be
found in the Additional file 1: Table S3. In Manhiça dis-
trict the demonstration programme of HPV vaccination
was executed by the MoH, using resources provided by
GAVI following a school-based delivery strategy [24].
The MoH transferred some of the resources to the
programme partners, such as CISM and FDC. Add-
itional file 1: S4 details the role of the participant
institutions.
UNICEF was the procurement agent for the HPV vac-
cine and equipment. Bivalent Cervarix® (two-dose vial)
was the formulation used for the programme at a re-
duced procurement price of US$5.70 per dose. We
added a 10% cost increase associated with custom clear-
ance, such as boarding inspection, taxes or the transport
cost to the central storage. While the vaccine price was
fully covered by GAVI, costs related to custom clearance
were paid by the MoH.
The main outputs of the programme implemented in
Manhiça district are shown in Table 1. Three central
level EPI supervisors were trained and assigned to over-
see the programme implementation. This implied regu-
lar supervision visits from central to district level
(US$64 per diem, per person). In total, 21 health pro-
fessionals formed the active vaccination workforce in
the district, with an average of 1.75 professionals per
health facility catchment area to implement the
programme during the first cycle (2014). However, two
health professionals were assumed for calculation pur-
poses to reflect the realistic scenario per health facility
catchment area. Each health professional received
US$48 per diem to deliver the vaccine at each school
visit. According to district EPI data, the demonstration
programme achieved 2,276 FIGs, 77% of the target
population, and 6,945 doses were estimated to be ad-
ministered throughout the 2014 cycle. The remaining
23% were girls who were not enrolled at school or were
absent at vaccination time. The latter were informed by
teachers that they could get vaccinated at health facil-
ities. In the 2014 cycle, vaccination only occurred at
schools. However, efforts were made to also reach and
vaccinate girls at health facilities and at the community
in case girls were not found at school. Despite such
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efforts, only two girls were tracked to get the vaccine at
a health facility through an active search team in Mal-
uana administrative post.
Cost of the first HPV vaccination cycle implemented in
Manhiça district
The total economic cost of the programme for the 2014
cycle was US$122,170 of which US$42,163 was financial.
These amounts represent the total value of the resources
used in the district of Manhiça in 2014, including re-
sources used at national, provincial and district levels, and
costs at health facilities and schools. Total amounts in-
cluded vaccination at schools with an achieved coverage
of 77%. No improvement in cold-chain capacities was re-
quired to implement the programme in Manhiça due to
existing space capacity.
Table 2 shows the total financial and economic costs
of the HPV vaccination programme for the 2014 cycle.
Concerning financial costs, most of the resources
used were recurrent costs (US$36,577) and consisted
of vaccine procurement (US$12,774), service delivery
(US$8,804), monitoring and evaluation (US$13,086)
and waste management (US$1,914). Introduction fi-
nancial costs attributable to the 2014 cycle were
US$5,585 and consisted of microplanning and training
activities (US$2,484) and social mobilisation and IEC
Table 1 Annual outputs of the human papillomavirus (HPV) demonstration programme in the Manhiça district for the 2014 cycle
and the alternative scenario
Annual outputs Demonstration Programme (2014 cycle) Alternative scenario
# doses required to fully immunise a girl 3 2
# supervisors trained 3 1
# vaccinators per health facility 1 1
# vaccinators at schools 2 1
# start-up vaccination facility catchment areaa 12 12
# start-up primary schoolsb 92 92
Number of fully-immunised girls (FIGs)c 2,276 2,791
Total doses of vaccine administeredc 6,945 5,648
% of the total target population fully immunised 77% 94%
Notes:
aA total of 12 health facilities with EPI services were present in the district.
b92 schools according to the official list of MoE (Additional file 1: Table S5).
cNumber of fully-immunised girls (FIGs) and doses obtained from district coverage data.
Table 2 Financial and economic costs of the 2014 vaccination cycle (US$)
FINANCIAL COSTS ECONOMIC COSTS
Introduction costsa
Microplanning and training 2,484 5.89% 6,232 5.10%
Social mobilisation – IECb 3,101 7.36% 3,653 2.99%
Subtotal introduction costs 5,585 13.25% 9,885 8.09%
Recurrent costs
Vaccine procurementc 12,774 30.30% 64,237 52.58%
Service delivery 8,804 20.88% 29,367 24.04%
Supervision, monitoring & evaluation 13,086 31.04% 13,086 10.71%
Other recurrent costs 1,914 4.54% 1,914 1.57%
Subtotal recurrent costs 36,577 86.75% 108,604 88.90%
Cold-chain supplementc
Subtotal cold-chain supplement 0 0.00% 3,681 3.01%
Total costs 42,163 122,170
Note:
aIntroduction costs were annualised in five years and only the first year amount was attributable for the 2014 vaccination cycle
bIEC information, education and communication
cThe total vaccine procurement economic cost (US$64,237) was the sum of custom clearance, syringes and safety boxes costs (US$12,774), considered both
financial and economic costs, and the vaccine price (US$56,610), treated as economic cost. The use of existing cold-chain excess capacity (US$3,681) was
considered economic cost. Other economic costs were capital and labour costs, which incurred in opportunity costs
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activities (US$3,101). When considering economic
costs, the total cost of the programme reached
US$122,170. This increase (US$80,007) was mainly
explained by adding the vaccine price (US$51,463) to
the procurement economic cost (US$64,237) and the
use of existing cold-chain excess capacity in the dis-
trict (US$3,681). The increase in the economic costs
of service delivery (US$20,563), microplanning and
training activities (US$3,748) and social mobilisation
and IEC activities (US$552) was due to the opportun-
ity cost of labour and vehicles already existing in the
health system. A graphical representation of the eco-
nomic costs is shown in Fig. 1. Vaccine procurement
represented up to 53% of the total economic cost, be-
ing the largest recurrent and total economic cost of
the programme. Service delivery reached 24% of the
total economic cost, while monitoring and evaluation
represented 11%. Microplanning and training contrib-
uted 5%; social mobilisation and IEC activities and
cold-chain utilisation of excess capacity contributed
3% each to the total. Other recurrent economic costs
(1%) completed the programme disbursements, con-
sisting of the waste management.
Table 3 shows the financial and economic cost per
dose and per FIG. The average economic cost delivered
was US$17.59 per dose (US$6.07 financial cost per dose),
of which US$1.42 corresponded to introduction,
US$15.64 to recurrent and US$0.53 to cold-chain eco-
nomic cost. The demonstration programme (cycle 2014)
implied an average economic cost of US$52.29 per FIG
(US$17.95 financial cost per FIG).
Costs of the alternative scenario
We estimated the programme cost if the number of
doses were reduced to two; the supervision team to one
supervisor and the outreach team at schools to one
vaccinator and one teacher; and if two community out-
reach visits were carried out per health facility catch-
ment area, in order to increase the coverage of FIGs to
94% of the target population (Table 1). This set of
changes implied a reduction in the vaccine procurement
economic cost from US$64,237 to US$52,241. It also im-
plied a reduction in the service delivery economic cost
from US$29,367 to US$13,283, as well as supervision
cost from US$13,086 to US$7,401 as the reduction of
supervisors compensated the community outreach costs.
All in all, the programme economic cost would reduce
to US$87,718 (US$28,223 financial costs). Financial and
economic costs of the alternative scenario can be found
in the Additional file 1: Table S6.
The average economic cost reduced to US$15.53 per
dose (US$5.00 financial cost per dose), US$1.75 corre-
sponding to introduction, US$13.25 to recurrent and
US$0.53 to cold-chain economic costs. The average eco-
nomic and financial cost per FIG reduced to US$31.14
and US$9.99 respectively (Table 3).
Discussion
During the first vaccination cycle of the demonstration
programme in Manhiça district, when three doses were
administered, the average financial cost per dose was
US$6.07 (US$17.59 economic). Our estimations were
below the mean financial (US$8.74) and economic cost
per dose (US$19.98) recently calculated in a study report-
ing the findings of 12 demonstration projects in different
LMICs, ten of which were sub-Saharan African countries
[19]. However, our estimations of the average financial
(US$17.95) and economic (US$52.29) cost per FIG were
higher than most of those obtained by other published
studies reporting estimates of similar HPV vaccine dem-
onstration programmes in LMICs [15, 20–22].
Fig. 1 Economic costs of the human papillomavirus (HPV) vaccination programme (2014 cycle) in the Manhiça district expressed as (a) US$ and
(b) percentages
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Nonetheless, cross-country comparisons should be made
with caution. First, our estimations refer to the Manhiça
demonstration programme and no scale-up projection for
the introduction of the vaccine at a national level was com-
puted due to limited data on key variables, such as reliable
target population and number of schools. Second, there is a
great cost variability across countries [21]: the average fi-
nancial cost per FIG ranged from US$2.49 in India, under a
school-based delivery strategy and community outreach
services, to US$20.36 in Vietnam, also under a school-
based delivery strategy. However, two pilot projects evalu-
ated in Tanzania are likely to be more comparable to the
programme in Manhiça: population size and density were
similar, both followed a school-based delivery strategy,
achieved similar coverage levels to that in Manhiça (79 and
72%) and resulted in similar average financial cost per FIG
(US$15.27 and US$19.17) but higher average economic
costs per FIG (US$66 to US$78) due to higher transport
and storage costs [21, 22].
The high average financial cost per FIG in Manhiça
(US$17.95) is mainly explained by the lower coverage
rate achieved (77%) than most of other demonstration
programmes, and by certain country characteristics,
such as: (1) low population density [19], (2) long dis-
tance between health facilities and schools, and (3)
programme design with high intensity of resources de-
voted to the programme [19].
The school-based delivery strategy has important im-
plications in terms of coverage that critically affects the
cost per FIG in low-income countries: (1) school-based
vaccine programmes face poor planning, and (2) high
percentage of school absenteeism and out-of-school
girls are commonly reported [13]. According to the
Mozambican National Institute of Statistics, 2,974 ten-
year-old girls lived in Manhiça district at the time of
the first cycle [24], but only 2,280 were enrolled at
schools according to the school census. It implies that
694 girls (23.34% of the target population) could not be
reached following a school-based approach, therefore
reducing the coverage and increasing the cost per FIG.
One possibility is to increase the coverage through
community visits of outreach services to reach girls in
remote settings [37]. Assuming two community visits
per health facility catchment area, and under a three-
dose regime, the average economic cost per dose would
decrease to US$17.11 as coverage increases (94%).
However, the average economic cost per FIG would still
remain high (US$52.03) due to the increased number of
vaccines administered: procurement of US$77.52 and
delivery of US$36.35. Alternatively, a reduction in the
supervision team to one and the outreach team at
schools to one vaccinator and one teacher would di-
minish the total cost to US$101,629 (17%) due to halv-
ing the vaccine delivery cost to US$14,683 and
reducing supervision to US$7,218, allowing a reduction
in the average financial cost per FIG to US$13.44
(US$43.26 economic cost). Finally, should the two-
doses regimen have been implemented during the 2014
cycle, it would have allowed reducing the overall eco-
nomic cost of the programme (US$90,128; 26%) due to
reductions in the vaccine procurement (US$43,190;
32.76%) and delivery (US$19,578; 33.33%), yielding to a
decrease in the average economic cost per FIG to
US$37.89, thanks to savings in number of school visits.
A combination of these three measures would reduce
the average economic cost to US$15.53 per dose
(US$5.00 financial) and to US$31.14 per FIG (US$9.99
financial).
Demonstration programmes in LMICs have been re-
ported to be resource-intensive, but national vaccine im-
plementation should involve substantial economies of
scales [19]. The Mozambican MoH projected an HPV
vaccination cost of US$39 per FIG through the routine
EPI schedule, lower than the one obtained in our study
[38]. However, it is important to note that Manhiça is
dissimilar to other districts, due to its atypical socio-eco-
nomic characteristics and circumstances related to its
healthcare network privileged by the presence of a re-
search institution. Thus, if Mozambique is to implement
HPV vaccination targeted at ten-year-old girls in schools
Table 3 Average financial and economic costs per dose and fully-immunised girl (FIG) for the demonstration programme (2014
cycle) and the alternative scenario (US$)
Financial Cost Economic Cost
Introduction cost Recurrent cost Cold-chain Total cost Introduction cost Recurrent cost Cold-chain Total cost
Demonstration
Programme
(2014 cycle)
Cost per dose 0.80 5.27 0.00 6.07 1.42 15.64 0.53 17.59
Cost per FIG 1.88 16.07 0.00 17.95 3.32 47.73 1.24 52.29
Alternative scenario
Cost per dose 0.99 4.01 0.00 5.00 1.75 13.25 0.53 15.53
Cost per FIG 1.88 8.11 0.00 9.99 3.32 26.81 1.01 31.14
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with minimal cold-chain requirements fulfilled, cuts
must be made to the use of resources. First, reduction in
the outreach team to one vaccinator and one teacher
should be considered. Second, the need for subsistence
support to the team as well as constant supervisory visits
should be revisited. Further, despite the EPI, the MoH
will most likely rely on implementation partners to sup-
port training, IEC and transport of the brigades in the
field, and approaches to sustainability should be
addressed.
The evaluation of alternative delivery mechanisms of
HPV vaccination either under a health facility delivery
strategy or as part of existing programmes (adolescent
health programmes) would reveal which strategies are
most efficient and less costly in the Mozambican con-
text [39, 40].
Conclusion
The estimation of the demonstration programme to de-
liver HPV vaccination in Manhiça reached an average fi-
nancial cost of US$6.07 per dose and of US$17.95 per
FIG (economic cost of US$17.59 per dose and
of US$52.29 per FIG). The cost per dose was below the
one reported from similar demonstration programmes
in other LMICs but the cost per FIG was among the
highest as out-of-school girls limited vaccination cover-
age. However, the financial cost per FIG could be re-
duced to US$9.99 (US$31.14 economic) under a two-
dose schedule, combined with an improvement in vac-
cine coverage and reductions in personnel costs. None-
theless, the vaccine preventive effect might sharply
reduce the number of cervical cancer cases in
Mozambique despite the high costs and challenges of a
national scale-up of the intervention.
Additional file
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Abbreviations
CISM: Centro de Investigação em Saúde de Manhiça; DALY: Disability-adjusted
life year; EPI: Expanded programme on immunisation; FDC: Fundação para o
Desenvolvimento da Comunidade; FIG: Fully immunised girl; GAVI: Global
Alliance for Vaccines and Immunisations; GNI: Gross national income;
HPV: Human papillomavirus; IEC: Information, education and communication;
LMIC: Low- and middle-income country; MoE: Ministry of Education;
MoH: Ministry of Health; UNICEF: United Nations International Children’s
Emergency Fund; WHO: World Health Organisation
Acknowledgments
The authors thank all participants from the Ministry of Health and Education,
as well as their District and Provincial Directorates, for their involvement in
the project.
Ethics and approval consent to participate
The viability studies to implement the HPV vaccination programme were
approved by the Institutional Review Board of the Manhiça Health Research
Centre (CIBS-CISM). Formal letters and email messages were sent to study
participants and written consent to participate was obtained by email prior
to interviews.
Authors’ contributions
KM, CM, GM and EsS designed the study. GM and EM established
connection with key participants. SA undertook the interviews and collected
data with the support of YM and OC and the supervision of EM and KM. SA
analysed the data. SA, ElS, EM and KM interpreted the data. SA, ElS and KM
wrote the first version of the manuscript. All authors read and approved the
final manuscript.
Funding
The study was funded by GAVI, the Vaccine Alliance, and was executed by
the Mozambican Ministry of Health. The Manhiça Health Research Centre
(CISM) designed the study using standardised tools developed by the World
Health Organisation (WHO).
CISM is supported by the Government of Mozambique and the Spanish
Agency for International Development (AECID). ISGlobal is a member of the
CERCA Programme, Generalitat de Catalunya.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Consent for publication
Not applicable.
Competing interests
None declared.
Author details
1CISM (Centro de Investigação em Saúde de Manhiça), Bairro Cambeve, Rua
12, Distrito da Manhiça, Maputo CP 1929, Mozambique. 2ISGlobal, Hospital
Clínic, Universitat de Barcelona, Barcelona, Spain. 3Centre for Primary Care
and Public Health, Barts and The London School of Medicine & Dentistry,
Queen Mary University of London, London, UK. 4Expanded Program on
Immunisation (EPI), Ministry of Health, Maputo, Mozambique. 5Health
Economics group, School of Public Health, Department of Infectious Disease
Epidemiology, Imperial College London, London, UK. 6Faculty of Medicine,
Eduardo Mondlane University, Maputo, Mozambique.
Received: 8 March 2019 Accepted: 18 July 2019
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. World Health Organization. Cervical cancer, human papillomavirus (HPV),
and HPV vaccines - Key points for policy-makers and health professionals.
Geneva 2007. Available from: https://www.who.int/reproductivehealth/
publications/cancers/RHR_08_14/en/.
3. ICO Information Centre on HPV and Cancer. Mozambique. Human
Papillomavirus and Related Cancers, Fact Sheet 2017. 2017;
4. Lorenzoni C, Vilajeliu A, Carrilho C, Ismail MR, Castillo P, Augusto O, et al.
Trends in cancer incidence in Maputo, Mozambique, 1991-2008. PLoS One.
2015;10(6):1–12.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et
al. Human papillomavirus is a necessary cause of invasive cervical cancer
worldwide. J Pathol. 1999;189(1):12–9.
6. World Health Organization. Comprehensive cervical Cancer control. WHO
Libr cat data, vol. 364; 2014. Available from: http://www.who.int/
reproductivehealth/publications/cancers/cervical-cancer-guide/en/
7. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al.
Global estimates of human papillomavirus vaccination coverage by region
and income level: a pooled analysis. Lancet Glob Heal. 2016;4(7):e453–63.
Alonso et al. BMC Public Health         (2019) 19:1031 Page 8 of 9
8. LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Badiane O,
Ndiaye C. Progress in HPV vaccination in low- and lower-middle-income
countries. Int J Gynecol Obstet. 2017;138:7–14.
9. UNICEF. Vaccine price data. 2017. Available from: https://www.unicef.org/
supply/files/HPV_.pdf. [cited 2018 Jan 29]
10. Hanson C, Eckert L, Bloem P, Cernuschi T. Gavi HPV programs: application to
implementation. Vaccines. 2015;3(2):408–19 Available from: http://www.
mdpi.com/2076-393X/3/2/408/.
11. Toh ZQ, Licciardi PV, Russell FM, Garland SM, Batmunkh T, Mulholland EK. Cervical
Cancer prevention through HPV vaccination in low- and middle-income
countries in Asia. Asian Pac J Cancer Prev. 2017;18(9):2339–43.
12. Kim JJ, Campos NG, O’Shea M, Diaz M, Mutyaba I. Model-based impact and
cost-effectiveness of cervical cancer prevention in sub-saharan Africa.
Vaccine. 2013;31(S5):F60–72. https://doi.org/10.1016/j.vaccine.2012.07.093.
13. Wigle J, Coast E, Watson-Jones D. Human papillomavirus (HPV) vaccine
implementation in low and middle-income countries (LMICs): health system
experiences and prospects. Vaccine. 2013;31(37):3811–7. https://doi.org/10.1
016/j.vaccine.2013.06.016.
14. Gallagher KE, Lamontagne DS, Watson-jones D. Status of HPV vaccine
introduction and barriers to country uptake. Vaccine. 2018;36(32):4761–7.
https://doi.org/10.1016/j.vaccine.2018.02.003.
15. Levin CE, Van Minh H, Odaga J, Rout SS, Ngoc DNT, Menezes L, et al.
Delivery cost of human papillomavirus vaccination of young adolescent
girls in Peru, Uganda and Viet Nam. Bull World Health Organ. 2013;91(8):
585–92. Available from: https://www.who.int/bulletin/volumes/91/8/12-113
837-ab/en/.
16. Gallagher KE, Howard N, Kabakama S, Mounier-Jack S, Burchett HED,
LaMontagne DS, et al. Human papillomavirus (HPV) vaccine coverage
achievements in low and middle-income countries 2007–2016. Papillomavirus
Res. 2017;4(October):72–8. https://doi.org/10.1016/j.pvr.2017.09.001.
17. Fregnani JHTG, Carvalho AL, Eluf-Neto J, Ribeiro K de CB, Kuil L de M, da Silva
TA, et al. A school-based human papillomavirus vaccination program in
Barretos, Brazil: final results of a demonstrative study. PLoS One. 2013;8(4):1–9.
18. Bonner K, Banura C, Basta NE. HPV vaccination strategies targeting hard-to-
reach populations: out-of-school girls in LMICs. Vaccine. 2017;36(2):191–3.
Available from: https://www.sciencedirect.com/science/article/pii/S026441
0X1731602X?via%3Dihub.
19. Botwright S, Holroyd T, Nanda S, Bloem P, Griffiths UK, Sidibe A, et al.
Experiences of operational costs of HPV vaccine delivery strategies in
Gavi-supported demonstration projects. PLoS One. 2017;12(10):1–13.
20. Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, et al. A case study
using the United Republic of Tanzania: costing nationwide HPV vaccine
delivery using the WHO cervical Cancer prevention and control costing
tool. BMC Med. 2012;10:136.
21. Levin A, Wang SA, Levin C, Tsu V, Hutubessy R. Costs of Introducing and
Delivering HPV Vaccines in Low and Lower Middle Income Countries: Inputs
for GAVI Policy on Introduction Grant Support to Countries. PLOS ONE.
2014;9(6):e101114. https://doi.org/10.1371/journal.pone.0101114.
22. Quentin W, Terris-prestholt F, Changalucha J, Soteli S, Edmunds WJ,
Hutubessy R, et al. Costs of delivering human papillomavirus vaccination to
schoolgirls in Mwanza region, Tanzania. BMC Med. 2012;10:137.
23. Moon TD, Silva-Matos C, Cordoso A, Baptista AJ, Sidat M, Vermund SH.
Implementation of cervical cancer screening using visual inspection with
acetic acid in rural Mozambique: successes and challenges using HIV care
and treatment programme investments in Zambézia Province. J Int AIDS
Soc. 2012;15(2):2–8.
24. Department of Public Health – Expanded Program on Immunization. Ministry
of Health. Republic of Mozambique. HPV demonstration programme – year 1.
Mozambique: Technical report on the post-introduction evaluation of HPV
vaccine in Manhiça; 2015.
25. GAVI the Vaccine Alliance. GAVI supporting guidelines. 2018. Available
from: http://www.gavi.org/support/process/apply/. [cited 2017 Jan 26]
26. Instituto Nacional de Estadística. Estatísticas do Distrito de Manhiça. Maputo,
Republic of Mozambique; 2013.
27. Sacoor C, Nhacolo A, Nhalungo D, Aponte JJ, Bassat Q, Augusto O, et al.
Profile: Manhiça Health Research Centre (Manhiça HDSS). Int J Epidemiol.
2013;42(5):1309–18. Available from: https://academic.oup.com/ije/
article/42/5/1309/621438.
28. Burchett HED, Mounier-Jack S, Torres-Rueda S, Griffiths UK, Ongolo-Zogo P,
Rulisa S, et al. The impact of introducing new vaccines on the health
system: case studies from six low- and middle-income countries. Vaccine.
2014;32(48):6505–12. https://doi.org/10.1016/j.vaccine.2014.09.031.
29. Ministry of Health. Republic of Mozambique. Relatório da
implementação da tercera dose de HPV a nível distrito da Manhiça.
Maputo; 2014.
30. World Health Organization. WHO Cervical Cancer Prevention and Control
Costing Tool (C4P). 2015. Available from: http://www.who.int/immunization/
diseases/hpv/cervical_cancer_costing_tool/en/. [cited 2018 Jan 11]
31. The World Bank. Official exchange rate (LCU per US$, period average). [cited
2018 Jan 11]. Available from: https://data.worldbank.org/indicator/PA.NUS.
FCRF?end=2014&start=1960.
32. Johns B, Baltussen R, Hutubessy R. Programme costs in the economic
evaluation of health interventions. Cost Eff an Resour Alloc. 2003;1:1.
33. World Health Organization. Guidelines for estimating costs of introducing
new vaccines into the national immunization system. World Health
Organization. 2002. https://apps.who.int/iris/handle/10665/67342.
34. Lee B, Haidari L, Prosser W, Connor D, Bechtel R, Dipuve A, et al. Re-designing
the Mozambique vaccine supply chain to improve access to vaccines. Vaccine.
2016;34(41):4998–5004.
35. Ministério de Saúde em colaboração com OMS e UNICEF. Plano de
Reabilitação e Expansão da Cadeia de Frio de Vacinas – Primeira
Actualização. Maputo; 2014.
36. World Health Organization. Evidence based recommendations on Human
Papilloma Virus (HPV) Vaccines Schedules. Background paper for SAGE
discussions. 2014. Available from: http://www.who.int/immunization/sage/
meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_
Appendices2_3.pdf?ua=1
37. Roodenbeke E De, Lucas S, Rouzaut A, Bana F. Outreach services as a
strategy to increase access to health workers in remote and rural areas.
Technical Report No2. World Heal Organ [Internet]. 2011;(2):48. Available
from: https://www.who.int/hrh/resources/outreach/en/.
38. Dutta A, Perales N, Silva R, Cirera i, Crivillé L. Necessidades de recursos
estimados e impacto do plano estratégico do sector de saúde de
Moçambique, 2014–2019. Maputo; 2014.
39. Burger EA, Campos NG, Sy S, Regan C, Kim JJ. Health and economic
benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine.
2018;36(32):4823–9. https://doi.org/10.1016/j.vaccine.2018.04.061.
40. Chido-A, Onyema G, et al. A call for the introduction of gender-neutral HPV
vaccination to national immunisation programmes in Africa. The Lancet
Global Health. 7(1):e20-1.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Alonso et al. BMC Public Health         (2019) 19:1031 Page 9 of 9
